{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:38:39Z","timestamp":1782401919447,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cytomegalovirus (CMV) colitis is a significant entity in hospitalized patients with ulcerative colitis, particularly during immunosuppressive therapy. The factors associated with antiviral treatment duration remain incompletely defined. This retrospective cohort study included hospitalized adult patients with ulcerative colitis and immunohistochemically confirmed CMV colitis. Baseline demographic, clinical, endoscopic, and laboratory characteristics were evaluated for the cohort and stratified by antiviral treatment duration of \u226414 days and &gt;14 days. Correlation analyses were performed between tissue CMV polymerase chain reaction (PCR) viral load and laboratory parameters. Receiver operating characteristic analysis identified a tissue CMV PCR cut-off associated with prolonged antiviral therapy. The study included 52 patients (median age, 41.5 years; 65.4% male). Fourteen patients received biologic therapy and were younger and had higher C-reactive protein levels than those who did not receive biologics. Tissue CMV PCR viral load was higher in patients who received antiviral therapy for &gt;14 days. The analysis identified a tissue CMV PCR cut-off value of 162,000 IU\/mg, with an area under the curve of 0.69, sensitivity of 70.4%, and specificity of 76.0%. Tissue CMV PCR viral load showed a weak negative correlation with serum albumin levels (Spearman \u2019s r = \u22120.34, p &lt; 0.05). Tissue CMV PCR viral load is associated with antiviral treatment duration and may help identify patients with ulcerative colitis\u2013associated CMV colitis who require prolonged therapy.<\/jats:p>","DOI":"10.3390\/v18020188","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:09:22Z","timestamp":1769771362000},"page":"188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Characteristics and Predictors of Antiviral Treatment Duration in Hospitalized Patients with Ulcerative Colitis-Associated Cytomegalovirus Colitis, Including Biologic Therapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-7224","authenticated-orcid":false,"given":"\u00d6zlem","family":"G\u00fcler","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, 41001 \u0130zmit, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Kocaeli University, 41001 \u0130zmit, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3904\/kjim.2017.087","article-title":"Approach to Cytomegalovirus Infections in Patients with Ulcerative Colitis","volume":"32","author":"Park","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Soni, K., and Puing, A. (2025). Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease. Viruses, 17.","DOI":"10.3390\/v17060752"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Qin, Y., Wang, G., Kong, D., Li, G., Wang, H., Qin, H., and Wang, H. (2021). Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11111952"},{"key":"ref_4","first-page":"005309","article-title":"Potential Role of Upadacitinib in Cytomegalovirus Colitis Recurrence","volume":"12","author":"Tsujinaka","year":"2025","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"335","author":"Altman","year":"2007","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4253\/wjge.v8.i6.301","article-title":"Characteristic Endoscopic Findings and Risk Factors for Cytomegalovirus-Associated Colitis in Patients with Active Ulcerative Colitis","volume":"8","author":"Hirayama","year":"2016","journal-title":"World J. Gastrointest. Endosc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00365521.2020.1740778","article-title":"The Use of ICD Codes to Identify IBD Subtypes and Phenotypes of the Montreal Classification in the Swedish National Patient Register","volume":"55","author":"Shrestha","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_8","first-page":"462","article-title":"How to Assess Endoscopic Disease Activity in Ulcerative Colitis in 2022","volume":"35","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Luciani, L., Mongin, D., Ninove, L., Nougair\u00e8de, A., Bardy, K., Gazin, C., Charrel, R.N., and Zandotti, C. (2021). Cytomegalovirus Viral Load in Transplanted Patients Using the NeuMoDxTM (Qiagen) Automated System: A 1-Month Experience Feedback. Viruses, 13.","DOI":"10.3390\/v13081619"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yang, H., Wu, K., Zhang, H., Owyang, Q., Miao, Y., Gu, F., Hu, N., Zou, K., Sheng, J., and Li, J. (2020). IgA, Albumin, and Eosinopenia as Early Indicators of Cytomegalovirus Infection in Patients with Acute Ulcerative Colitis. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01434-5"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcv.2018.06.002","article-title":"Novel Score Predicts Risk for Cytomegalovirus Infection in Ulcerative Colitis","volume":"105","author":"Nowacki","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation Coefficients: Appropriate Use and Interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth. Analg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11894-021-00829-y","article-title":"Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review Safety of Anti-TNF, Anti-Integrin, Anti IL-12\/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine\/6-MP and Methotrexate)","volume":"23","author":"Sattler","year":"2021","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3748\/wjg.v16.i10.1245","article-title":"Specific Endoscopic Features of Ulcerative Colitis Complicated by Cytomegalovirus Infection","volume":"16","author":"Suzuki","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1097\/MIB.0000000000000958","article-title":"Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis","volume":"22","author":"Beswick","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hsieh, C.-R., Wu, R.-C., Kuo, C.-J., Yeh, P.-J., Yeh, Y.-M., Chen, C.-L., Chiu, C.-T., Chiu, C.-H., Pan, Y.-B., and Tsou, Y.-K. (2024). Adequate Antiviral Treatment Lowers Overall Complications of Cytomegalovirus Colitis among Inpatients with Inflammatory Bowel Diseases. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09317-w"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e28359","DOI":"10.1097\/MD.0000000000028359","article-title":"Optimal Duration of Antiviral Treatment in Patients with Gastrointestinal Cytomegalovirus Disease at a Low and High Risk of Relapse","volume":"101","author":"Jung","year":"2022","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ecco-jcc\/jjaa036","article-title":"Ulcerative Colitis and Cytomegalovirus Infection: From A to Z","volume":"14","author":"Mourad","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3748\/wjg.v22.i6.2030","article-title":"Cytomegalovirus and Ulcerative Colitis: Place of Antiviral Therapy","volume":"22","author":"Pillet","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17474124.2022.2032662","article-title":"Cytomegalovirus in Ulcerative Colitis: An Evidence-Based Approach to Diagnosis and Treatment","volume":"16","author":"Jena","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Okahara, K., Nagata, N., Shimada, T., Joya, A., Hayashida, T., Gatanaga, H., Oka, S., Sakurai, T., Uemura, N., and Akiyama, J. (2017). Colonic Cytomegalovirus Detection by Mucosal PCR and Antiviral Therapy in Ulcerative Colitis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183951"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/ibd\/izaf129","article-title":"Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients with Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study","volume":"31","author":"Kochhar","year":"2025","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:13:04Z","timestamp":1769771584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020188"],"URL":"https:\/\/doi.org\/10.3390\/v18020188","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}